The risk of cancer goes up with age, in part because aging impedes the body's ability to detect and destroy cells with ...

Ivonescimab plus chemotherapy improved survival in advanced squamous NSCLC vs tislelizumab and chemotherapy in a phase 3 trial.

Akeso and Summit Therapeutics’ giant-killing, PD-1xVEGF bispecific antibody ivonescimab has posted another phase 3 trial win in lung cancer, this time as part of a chemotherapy combination.

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

Details of the acimtamig oral presentation and AFM24 poster presentations are as follows: The full abstracts will be published online on May 22, 2025. More details about the programs for the 2025 ASCO ...

Oncology experts discuss de-escalation strategies that can reduce toxicity, save a billion in healthcare costs, and make lung ...

Analysts at BMO Capital Markets expect Summit and Akeso’s HARMONi-6 readout to put some pressure on Merck and its blockbuster ...

Summit Therapeutics shares rallied after its lung cancer drug candidate showed that it improved patients' longevity without the disease worsening in a late-stage trial. Shares of Summit rose 11% to ...

Robotic-assisted thoracic surgery for lung cancer showed a short learning curve and strong outcomes, with 5-year survival rates comparable to open surgery.

The regulatory approval in the EU comes approximately six months after Novocure secured FDA approval of the system.

Veteran actress Sharmila Tagore's early-stage lung cancer diagnosis has brought attention to zero-stage lung cancer, also ...

When a tumor starts to grow in the body, small bits of its genetic material may break away and float off into the bloodstream. | Clinical And Molecular Dx ...